Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (381-390 of 436) with videos related to

Pageof 44
Sort By:
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Hypertension (Dallas, Tex. : 1979)|September 18, 2024
Systolic Blood Pressure, Cardiovascular Health, and Neurocognition in AdolescentsStephen R Hooper, Marc B Lande, Joseph T Flynn, et al.
International Journal of Cardiology|May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGYSarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.
Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Pageof 44

Showing results (381-390 of 436) with videos related to

Sort By:
Pageof 44
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Hypertension (Dallas, Tex. : 1979)|September 18, 2024
Systolic Blood Pressure, Cardiovascular Health, and Neurocognition in AdolescentsStephen R Hooper, Marc B Lande, Joseph T Flynn, et al.
International Journal of Cardiology|May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGYSarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.
Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Pageof 44